Nimesulide's generic formulations found to be effective and safe to treat low back and knee osteoarthritis pain

Summaries 4 min 158

Font Size

Created On: 24/11/2020

Nimesulide's generic formulations found to be effective and safe to treat low back and knee osteoarthritis pain

A randomized, prospective, double-blinded, phase 4 clinical study was conducted to investigate the safety and efficacy of two generic formulations of nimesulide (a selective cyclooxygenase [COX] -2 inhibitor) in patients having symptomatic low back pain or knee osteoarthritis.

See All

Key take away

From the findings of a phase 4 trial, it was deduced that the generic formulations of nimesulide are equally effective in alleviating pain in patients with knee osteoarthritis or low back pain. Both formulations display a similar safety profile.

Background

Method

The study recruited 60 out-patients having knee osteoarthritis or low back pain. Participants were randomly allocated to either generic 1 (n=30) group or generic 2 (n=30) (100 mg 2 x/day for 20 days) group. The Visual Analogue Scale (VAS) was effectively used to assess pain intensity.

In the low back pain, the following parameters were assessed: Paravertebral muscle spasm (PVM), Lasegue's test, and sagittal mobility. In the knee osteoarthritis, the following parameters were estimated: motion, knee tendons sensitivity (KTS) to palpation, knee circumference. Adverse events witnessed by the participants, or noted by the researchers were recorded.

Result

In patients suffering from low back pain and knee osteoarthritis, the generic formulations remarkably diminished pain levels. The knee circumference and KTS to palpation were also lowered. Both generic copies showed good tolerability. The safety of both generics was comparable. The most frequent adverse effects were mild and depicted a similar rate in both groups.